Ionis Pharmaceuticals Inc (IONS) Stock: Analyzing the Quarterly Movement

In the past week, IONS stock has gone up by 3.80%, with a monthly gain of 11.04% and a quarterly plunge of -1.23%. The volatility ratio for the week is 2.36%, and the volatility levels for the last 30 days are 3.04% for Ionis Pharmaceuticals Inc The simple moving average for the last 20 days is 7.12% for IONS stock, with a simple moving average of -6.77% for the last 200 days.

Is It Worth Investing in Ionis Pharmaceuticals Inc (NASDAQ: IONS) Right Now?

Additionally, the 36-month beta value for IONS is 0.38. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 8 rating it as “hold,” and 1 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for IONS is 134.19M and currently, short sellers hold a 6.41% ratio of that float. The average trading volume of IONS on June 24, 2024 was 1.04M shares.

IONS) stock’s latest price update

The stock of Ionis Pharmaceuticals Inc (NASDAQ: IONS) has increased by 0.87 when compared to last closing price of 41.83. Despite this, the company has experienced a 3.80% gain in its stock price over the last five trading sessions. zacks.com reported 2024-06-19 that Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.

Analysts’ Opinion of IONS

Many brokerage firms have already submitted their reports for IONS stocks, with Bernstein repeating the rating for IONS by listing it as a “Mkt Perform.” The predicted price for IONS in the upcoming period, according to Bernstein is $44 based on the research report published on June 14, 2024 of the current year 2024.

Wolfe Research, on the other hand, stated in their research note that they expect to see IONS reach a price target of $58. The rating they have provided for IONS stocks is “Outperform” according to the report published on April 10th, 2024.

BofA Securities gave a rating of “Buy” to IONS, setting the target price at $62 in the report published on January 02nd of the current year.

IONS Trading at 5.23% from the 50-Day Moving Average

After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.50% of loss for the given period.

Volatility was left at 3.04%, however, over the last 30 days, the volatility rate increased by 2.36%, as shares surge +11.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.49% lower at present.

During the last 5 trading sessions, IONS rose by +4.03%, which changed the moving average for the period of 200-days by +6.28% in comparison to the 20-day moving average, which settled at $39.60. In addition, Ionis Pharmaceuticals Inc saw -16.60% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at IONS starting from BERTHELSEN SPENCER R, who sale 16,000 shares at the price of $40.29 back on Jun 17 ’24. After this action, BERTHELSEN SPENCER R now owns 147,257 shares of Ionis Pharmaceuticals Inc, valued at $644,640 using the latest closing price.

KLEIN JOSEPH III, the Director of Ionis Pharmaceuticals Inc, sale 6,000 shares at $42.71 during a trade that took place back on May 03 ’24, which means that KLEIN JOSEPH III is holding 0 shares at $256,277 based on the most recent closing price.

Stock Fundamentals for IONS

Current profitability levels for the company are sitting at:

  • -0.5 for the present operating margin
  • 0.98 for the gross margin

The net margin for Ionis Pharmaceuticals Inc stands at -0.49. The total capital return value is set at -0.16. Equity return is now at value -98.20, with -13.61 for asset returns.

Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.86 points at debt to capital in total, while cash flow to debt ratio is standing at -0.18. The debt to equity ratio resting at 6.07. The interest coverage ratio of the stock is -5.03.

Currently, EBITDA for the company is -322.84 million with net debt to EBITDA at -4.95. When we switch over and look at the enterprise to sales, we see a ratio of 10.09. The receivables turnover for the company is 150.97for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.37.

Conclusion

In conclusion, Ionis Pharmaceuticals Inc (IONS) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts